Literature DB >> 18461027

Frequency and predictors of ventilator-associated pneumonia recurrence: a meta-analysis.

Ilias I Siempos1, Zoe Athanassa, Matthew E Falagas.   

Abstract

Large clinical series focusing on the risk factors associated with recurrence after the onset of an initial episode of ventilator-associated pneumonia (VAP) produced inconsistent results. A meta-analysis would be helpful to shed light on the issue. Our objective was to estimate the frequency of VAP recurrence and to identify risk factors associated with it. PubMed, Scopus, Current Contents, and references of retrieved articles were searched without language restrictions. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using both the Mantel-Haenszel fixed-effect and the DerSimonian-Laird random effects models. The overall frequency of VAP recurrence in 969 patients of the seven eligible reports was 26.8%. Among the 20 evaluated risk factors, only acute lung injury/acute respiratory distress syndrome (OR, 1.76; 95% CI, 1.12-2.75) and shock (OR, 1.55; 95% CI, 1.01-2.41) at the day of diagnosis of the first VAP episode were found to be associated with VAP recurrence. There was also evidence, albeit inconsistent, that severity of illness at intensive care unit admission was associated with VAP recurrence. Recurrence involves almost one in four cases of VAP and is associated with acute lung injury/acute respiratory distress syndrome and shock, but not with first-episode causative pathogens. Recognition of these predictors may permit the timely implementation of measures to prevent recurrence of VAP.

Entities:  

Mesh:

Year:  2008        PMID: 18461027     DOI: 10.1097/SHK.0b013e31816f1f7c

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia.

Authors:  Owen R Albin; Oryan Henig; Twisha S Patel; Thomas S Valley; Jason M Pogue; Lindsay A Petty; John P Mills; Adamo Brancaccio; Emily T Martin; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

2.  Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial.

Authors:  Yin Mo; Timothy Eoin West; Graeme MacLaren; Suchart Booraphun; Andrew Yunkai Li; Gyan Kayastha; Yie Hui Lau; Yin Tze Chew; Ploenchan Chetchotisakd; Paul Anantharajah Tambyah; Direk Limmathurotsakul; Ben Cooper
Journal:  BMJ Open       Date:  2021-05-13       Impact factor: 2.692

3.  Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.

Authors:  Adrien Bouglé; Arnaud Foucrier; Hervé Dupont; Philippe Montravers; Alexandre Ouattara; Pierre Kalfon; Pierre Squara; Tabassome Simon; Julien Amour
Journal:  Trials       Date:  2017-01-23       Impact factor: 2.279

4.  New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant pathogen and poor outcome.

Authors:  Asmaa M Elbrolosy; Azza Z Labeeb; Dina M Hassan
Journal:  Infect Drug Resist       Date:  2019-02-11       Impact factor: 4.003

5.  Clinical epidemiology and outcomes of ventilator-associated pneumonia in critically ill adult patients: protocol for a large-scale systematic review and planned meta-analysis.

Authors:  John Mark M Gutiérrez; Annabelle R Borromeo; Allan L Dueño; Emmanuel D Paragas; Rosanta O Ellasus; Russel S Abalos-Fabia; Jerry A Abriam; Arnel E Sonido; Monina A Hernandez; Alain Jason A Generale; Roberto C Sombillo; Mary Grace C Lacanaria; Mae M Centeno; Jose Reinhard C Laoingco; John Anthony A Domantay
Journal:  Syst Rev       Date:  2019-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.